The Singapore Economic Review

Avantor Inaugurates Expanded Singapore Hub

Retrieved on: 
Tuesday, July 11, 2023
CGMP, EVP, NYSE, AVTR, SVP, Senior, EDB, Drug discovery, Head, Infrastructure Investment Facilitation Company, The Singapore Economic Review, Airline, Avantor, Biopharma LLC

Avantor today officially inaugurated its expanded Singapore Manufacturing & Distribution Hub.

Key Points: 
  • Avantor today officially inaugurated its expanded Singapore Manufacturing & Distribution Hub.
  • Standing from left to right: Christophe Couturier (EVP, Asia Middle East Africa, Avantor), Elaine Teo (SVP & Head, Investment Facilitation, Singapore EDB) and Narayana Rao Rapolu (VP, Biopharma, Asia Middle East Africa, Avantor).
  • Avantor's expanded Singapore Hub to bolster Asia Pacifics Biopharma ecosystem with enhanced manufacturing and distribution.
  • "Avantor's latest expansion of its Singapore hub enhances the supply of key materials and services required by biopharma manufacturers in Singapore and the region.

Reynold Lemkins Shines at "American Davos" with Ambition to Support HK IPO by Long-term Investment

Retrieved on: 
Friday, September 29, 2023
Social responsibility, Gandhi Global Family, IPO, Health, Politics, Perception, Opportunity, TMT, Multimedia, IP, Bangladesh Technical Education Board, Element, Investment, Economic development, Milken Institute, Bridgewater Associates, Artificial intelligence, ESG, The Singapore Economic Review, Cornerstone, Environment, HK, Film industry, Management, Security (finance)

Their discussions focused on how to drive economic development in Asia amid the current global landscape.

Key Points: 
  • Their discussions focused on how to drive economic development in Asia amid the current global landscape.
  • As a partner of the Milken Institute, The Reynold Lemkins Group ("Reynold Lemkins" or the "Group") was invited to attend the high-level summit as well as co-hosted one of the parallel forums focusing on global single family offices.
  • Reynold Lemkins also shares their perception of the Hong Kong IPO markets which they are currently focus on.
  • And 4Paradigm's IPO had the largest IPO market cap of exceeding HK$25 billion, making it top the HK IPOs of the year in TMT sector.

JIOS Aerogel® Secures New Investment from MegaChem to Fund its Aerogel and Thermal Blade® Plants

Retrieved on: 
Monday, September 18, 2023
MGT, EV, Scottish Aquaculture Innovation Centre, Cell, Plant, PCL, EDB, Growth, Entrepreneurship, The Singapore Economic Review, Transport, Safety, Renewable energy

The funding will support JIOS Aerogel's two plants in Southeast Asia: its aerogel production facility and its new Singapore site for fully automated production of its Thermal Blade®.

Key Points: 
  • The funding will support JIOS Aerogel's two plants in Southeast Asia: its aerogel production facility and its new Singapore site for fully automated production of its Thermal Blade®.
  • Stephen Kang, Co-Founder and Managing Director of JIOS Aerogel, enthusiastically expressed, "We are thrilled to welcome MGT and MegaChem as investors, further bolstering the burgeoning aerogel market within the electric vehicle battery industry.
  • JIOS Aerogel's cutting-edge breakthrough, the Thermal Blade®, leverages the exceptional properties of aerogels to deliver superior thermal protection for battery cells, significantly enhancing their safety and performance.
  • Mr Sidney Chew, Managing Director of MegaChem, also expressed his enthusiasm, saying, "JIOS Aerogel has demonstrated the effectiveness of their distinctive and cost-efficient approach to aerogel manufacturing.

JIOS Aerogel® Secures New Investment from MegaChem to Fund its Aerogel and Thermal Blade® Plants

Retrieved on: 
Monday, September 18, 2023
MGT, EV, Scottish Aquaculture Innovation Centre, Cell, Plant, PCL, EDB, Growth, Entrepreneurship, The Singapore Economic Review, Transport, Safety, Renewable energy

The funding will support JIOS Aerogel's two plants in Southeast Asia: its aerogel production facility and its new Singapore site for fully automated production of its Thermal Blade®.

Key Points: 
  • The funding will support JIOS Aerogel's two plants in Southeast Asia: its aerogel production facility and its new Singapore site for fully automated production of its Thermal Blade®.
  • Stephen Kang, Co-Founder and Managing Director of JIOS Aerogel, enthusiastically expressed, "We are thrilled to welcome MGT and MegaChem as investors, further bolstering the burgeoning aerogel market within the electric vehicle battery industry.
  • JIOS Aerogel's cutting-edge breakthrough, the Thermal Blade®, leverages the exceptional properties of aerogels to deliver superior thermal protection for battery cells, significantly enhancing their safety and performance.
  • Mr Sidney Chew, Managing Director of MegaChem, also expressed his enthusiasm, saying, "JIOS Aerogel has demonstrated the effectiveness of their distinctive and cost-efficient approach to aerogel manufacturing.

MeetKai Uses Best-in-class Digital Twin Technology to Recreate Silicon Box's $2 Billion Dollar 800,000 sqft Advanced Packaging Fab in Metaverse

Retrieved on: 
Thursday, July 20, 2023
Dai, Synthetic media, Silicon, Investment, Engineering, Generative, EDB, Growth, LOS, AI, The Singapore Economic Review, Sales

LOS ANGELES, July 20, 2023 /PRNewswire/ -- Today MeetKai, the leading conversational AI and metaverse company and Silicon Box, a cutting-edge semiconductor integration startup, unveiled its digital twin replica of Silicon Box's new and highly anticipated $2 billion advanced semiconductor packaging fab aimed at revolutionizing the chip manufacturing sector and solving key bottlenecks in advanced packaging capacity. Dedicated to facilitating further development of native supply chains and technologies in the industry, Silicon Box recently held the private grand opening of its physical 800,000 sq ft facility in Tampines, Singapore while celebrating the debut of MeetKai's digital replica in the metaverse, promising great opportunities to contribute to Silicon Box's business growth and talent development.

Key Points: 
  • MeetKai partners with Silicon Box to power a state of the art digital twin for training, simulation and monitoring.
  • LOS ANGELES, July 20, 2023 /PRNewswire/ -- Today MeetKai, the leading conversational AI and metaverse company and Silicon Box, a cutting-edge semiconductor integration startup, unveiled its digital twin replica of Silicon Box's new and highly anticipated $2 billion advanced semiconductor packaging fab aimed at revolutionizing the chip manufacturing sector and solving key bottlenecks in advanced packaging capacity.
  • "At MeetKai, we believe we have only barely touched the surface of what promises to be very fertile ground for enterprise and industrial use cases in the metaverse," said MeetKai Co-Founder and CEO, James Kaplan.
  • "We're extremely proud of MeetKai's leading edge metaverse and AI technology and its potential to power the global semiconductor industry in new and disruptive ways.

Significantly Reduce Manufacturing Cost and Increased Local Production: SCG Cell Therapy Opens State-of-the-art Cell Therapy Manufacturing Facility and R&D Centre in Singapore

Retrieved on: 
Wednesday, July 19, 2023
GMP, White House, Biotechnology, IPSC, Cell therapy, Innovation, Infection, Cell, SCG, Government, Ministry, Agency for Science, Technology and Research, Patient, CGMP, Risk, A*STAR, Agency, Outline of health sciences, Cancer, EDB, Growth, The Singapore Economic Review, R, Health Sciences Authority, Christy, FDA, HSA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ministry of Trade and Industry, Food, Pharmaceutical industry, Fine chemical, State, Science, Research

SCG Cell Therapy celebrates the opening of its new Cell Therapy Manufacturing Facility and R&D Centre, launching a new first-of-its-kind automatic cell therapy manufacturing system in Singapore, pioneering Singapore's Manufacturing 2030 Vision.

Key Points: 
  • SCG Cell Therapy celebrates the opening of its new Cell Therapy Manufacturing Facility and R&D Centre, launching a new first-of-its-kind automatic cell therapy manufacturing system in Singapore, pioneering Singapore's Manufacturing 2030 Vision.
  • Facility will substantially increase local production capacity while significantly reducing the cost of cell therapy.
  • In 2021, SCG collaborated with the Cell Therapy Facility of Singapore Health Sciences Authority (HSA-CTF) to validate its proprietary closed and automated cell therapy manufacturing system.
  • "Apart from the cGMP facility, SCG Cell Therapy is also opening an R&D centre to facilitate the research of its pipeline of cell therapy product candidates.

Bain & Company to acquire APAC arm of global venture-building studio Rainmaking

Retrieved on: 
Friday, July 7, 2023
Advanced Innovation Design Approach, Interview, Enterprise Singapore, Agriculture, Bain Capital, I&D, Natural Resources, Acquisition, Corporate venture capital, Engineering, Growth, Bain & Company, The Singapore Economic Review, SGD, SME, Airline, Rainmaking

SINGAPORE, July 6, 2023 /PRNewswire/ -- Bain & Company today announced that it intends to acquire the Asia Pacific arm of global venture-building and start-up development studio, Rainmaking, to help companies across the region better innovate, launch, and scale new businesses. The acquisition is subject to, and contingent upon, several conditions precedent to completion and is expected to close at the end of July 2023.

Key Points: 
  • SINGAPORE, July 6, 2023 /PRNewswire/ -- Bain & Company today announced that it intends to acquire the Asia Pacific arm of global venture-building and start-up development studio, Rainmaking, to help companies across the region better innovate, launch, and scale new businesses.
  • Both Bain and Rainmaking APAC were appointed to participate in the Corporate Venture Launchpad 2.0 program, a SGD 20 million initiative launched by the Singapore Economic Development Board.
  • Rainmaking is also a partner of Enterprise Singapore's Global Innovation Alliance to help more Singapore-based start-ups and tech SMEs access market opportunities in international markets.
  • Rainmaking APAC builds new start-up companies that leverage the advantages and scale strengths of corporate partners and co-founders.

Leaf Home™ Appoints Nina George as Chief Growth Officer

Retrieved on: 
Tuesday, June 20, 2023
Senior, Marketing, National University of Singapore, Deputy, National university, BrainPop, MBA, Acquisition, Lazard, Yahoo!, CGO, Economic development, Harvard Business School, The Singapore Economic Review, Software engineering, Water purification, Rent the Runway, Programmer, Video game, Management, Growth

NEW YORK, June 20, 2023 /PRNewswire/ -- Leaf Home™ — the leading provider of technology-driven home solutions including gutter protection, home safety, water purification, windows and doors, and other home enhancement products — announced today that Nina George has joined the company as Chief Growth Officer (CGO). In her new position, George will drive Leaf Home's expansion efforts across North America and further solidify the company's position as a category leader.

Key Points: 
  • NEW YORK, June 20, 2023 /PRNewswire/ -- Leaf Home ™ — the leading provider of technology-driven home solutions including gutter protection, home safety, water purification, windows and doors, and other home enhancement products — announced today that Nina George has joined the company as Chief Growth Officer (CGO).
  • In her new position, George will drive Leaf Home's expansion efforts across North America and further solidify the company's position as a category leader.
  • Prior to joining Leaf Home, George served as Chief Growth and Marketing Officer at BrainPOP, an education technology company, after being promoted from a previous role as Senior Vice President, Growth and Marketing.
  • "The experience and skills Nina brings to the Leaf Home team will make a significant impact to our operations," said Jon Bostock, CEO of Leaf Home.

Ambiq Achieves Milestone of Powering Over 200 Million IoT Devices

Retrieved on: 
Monday, June 12, 2023
Semiconductor, Contact tracing, ASEAN, Internet of things, COVID-19, IC, TraceTogether, Advance Developing Markets, Iwowe, EDB, Bluetooth, Growth, The Singapore Economic Review, Mobile phone, Renewable energy

AUSTIN, Texas and SINGAPORE, June 12, 2023 (GLOBE NEWSWIRE) -- Ambiq®, a leading developer of ultra-low-power semiconductor solutions that deliver a multifold increase in energy efficiency, achieved a key milestone of powering over 200 million IoT devices earlier this year.

Key Points: 
  • AUSTIN, Texas and SINGAPORE, June 12, 2023 (GLOBE NEWSWIRE) -- Ambiq®, a leading developer of ultra-low-power semiconductor solutions that deliver a multifold increase in energy efficiency, achieved a key milestone of powering over 200 million IoT devices earlier this year.
  • As part of this expansion, Ambiq is actively recruiting regional talents to bolster its team and support its global expansion.
  • The Center's expansion will enable Ambiq to establish an integrated circuit (IC) design team in Singapore for product development.
  • These devices are powered by the Ambiq Apollo3 Blue SoC, using Bluetooth signals to trace others nearby.

Thermo Fisher Scientific Expands Steriles Manufacturing and Research Capabilities in Asia-Pacific Region

Retrieved on: 
Friday, May 19, 2023
Biotechnology, Commercial Building & Real Estate, Manufacturing, Construction & Property, Other Health, Health, Pharmaceutical, Other Science, Medical Devices, Other Manufacturing, Science, Yee, Vaccine, Molecular biology, Senior, Education, Good manufacturing practice, Chromatography, Multimedia, Research, Thermo Fisher Scientific, Mass spectrometry, Norwich Pharma Services, CGMP, EDB, Bioprocess, The Singapore Economic Review, Economic Development Board, Airline, Management, Pharmaceutical industry, Fine chemical, Health care, Marketing

“Thermo Fisher Scientific's fill-finish manufacturing facility will enable end-to-end vaccine manufacturing to be carried out in Singapore.

Key Points: 
  • “Thermo Fisher Scientific's fill-finish manufacturing facility will enable end-to-end vaccine manufacturing to be carried out in Singapore.
  • This strategic investment in Singapore complements new research capabilities at Thermo Fisher Scientific's Customer Experience Center and Bioprocess Design Center, two other operational lab facilities that showcase the latest bioprocessing, life science, and analytical technologies.
  • Together, these sites allow Thermo Fisher to better enable customers to accelerate their research, as well as develop and commercialize new medicines and vaccines in the Asia-Pacific market.
  • In total, over 2,000 company employees are contributing to Singapore’s evolution as a biomedical hub in the Asia-Pacific region.